These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30187356)

  • 1. Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.
    Chang TC; Chin YT; Nana AW; Wang SH; Liao YM; Chen YR; Shih YJ; Changou CA; Yang YS; Wang K; Whang-Peng J; Wang LS; Stain SC; Shih A; Lin HY; Wu CH; Davis PJ
    Horm Cancer; 2018 Dec; 9(6):420-432. PubMed ID: 30187356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
    Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
    Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status.
    Lee YS; Chin YT; Yang YSH; Wei PL; Wu HC; Shih A; Lu YT; Pedersen JZ; Incerpi S; Liu LF; Lin HY; Davis PJ
    Steroids; 2016 Jul; 111():63-70. PubMed ID: 26980146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers.
    Nana AW; Wu SY; Yang YS; Chin YT; Cheng TM; Ho Y; Li WS; Liao YM; Chen YR; Shih YJ; Liu YR; Pedersen J; Incerpi S; Hercbergs A; Liu LF; Whang-Peng J; Davis PJ; Lin HY
    Horm Cancer; 2018 Oct; 9(5):349-360. PubMed ID: 30027502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different
    Chin YT; He ZR; Chen CL; Chu HC; Ho Y; Su PY; Yang YSH; Wang K; Shih YJ; Chen YR; Pedersen JZ; Incerpi S; Nana AW; Tang HY; Lin HY; Mousa SA; Davis PJ; Whang-Peng J
    Front Endocrinol (Lausanne); 2019; 10():130. PubMed ID: 30915033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.
    Lin HY; Chin YT; Nana AW; Shih YJ; Lai HY; Tang HY; Leinung M; Mousa SA; Davis PJ
    Steroids; 2016 Oct; 114():59-67. PubMed ID: 27221508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac.
    Sudha T; Bharali DJ; Yalcin M; Darwish NH; Coskun MD; Keating KA; Lin HY; Davis PJ; Mousa SA
    Nanomedicine (Lond); 2017 Feb; 12(3):195-205. PubMed ID: 28102776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NDAT suppresses pro-inflammatory gene expression to enhance resveratrol-induced anti-proliferation in oral cancer cells.
    Ho Y; Wu CY; Chin YT; Li ZL; Pan YS; Huang TY; Su PY; Lee SY; Crawford DR; Su KW; Chiu HC; Shih YJ; Changou CA; Yang YSH; Whang-Peng J; Chen YR; Lin HY; Mousa SA; Davis PJ; Wang K
    Food Chem Toxicol; 2020 Feb; 136():111092. PubMed ID: 31883986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nano-diamino-tetrac (NDAT) inhibits PD-L1 expression which is essential for proliferation in oral cancer cells.
    Lin SJ; Chin YT; Ho Y; Chou SY; Sh Yang YC; Nana AW; Su KW; Lim YT; Wang K; Lee SY; Shih YJ; Chen YR; Whang-Peng J; Davis PJ; Lin HY; Fu E
    Food Chem Toxicol; 2018 Oct; 120():1-11. PubMed ID: 29960019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac.
    Sudha T; Bharali DJ; Yalcin M; Darwish NH; Debreli Coskun M; Keating KA; Lin HY; Davis PJ; Mousa SA
    Int J Nanomedicine; 2017; 12():1305-1315. PubMed ID: 28243091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticulate Tetrac Inhibits Growth and Vascularity of Glioblastoma Xenografts.
    Sudha T; Bharali DJ; Sell S; Darwish NHE; Davis PJ; Mousa SA
    Horm Cancer; 2017 Jun; 8(3):157-165. PubMed ID: 28396979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
    Park JJ; Yi JY; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
    Biochem Pharmacol; 2012 Apr; 83(7):849-57. PubMed ID: 22266356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle.
    Li W; Yalcin M; Bharali DJ; Lin Q; Godugu K; Fujioka K; Keating KA; Mousa SA
    Sci Rep; 2019 Jun; 9(1):9006. PubMed ID: 31227723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells.
    Unson S; Chang TC; Yang YN; Wang SH; Huang CH; Crawford DR; Huang HM; Li ZL; Lin HY; Whang-Peng J; Wang K; Davis PJ; Li WS
    Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent.
    Rebbaa A; Chu F; Davis FB; Davis PJ; Mousa SA
    Angiogenesis; 2008; 11(3):269-76. PubMed ID: 18386142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts.
    Mousa SA; Yalcin M; Bharali DJ; Meng R; Tang HY; Lin HY; Davis FB; Davis PJ
    Lung Cancer; 2012 Apr; 76(1):39-45. PubMed ID: 22024450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
    Solberg NT; Waaler J; Lund K; Mygland L; Olsen PA; Krauss S
    Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.